Supervisors info:
Ευάγγελος Τέρπος, Καθηγητής, Ιατρική Σχολή ΕΚΠΑ
Μαρία Γαβριατοπούλου, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Ιωάννης Ντάνασης-Σταθόπουλος, Διδάκτωρ, Ιατρική Σχολή, ΕΚΠΑ
Summary:
Introduction: The use of bispecific antibodies has brought significant advancements in the treatment of hematological malignancies, such as leukemia, lymphoma, and multiple myeloma. These antibodies possess the unique ability to target two different antigens simultaneously, increasing effectiveness and reducing therapy side effects. This study examines the action, results, and prospects of bispecific antibodies in clinical practice. Methodology: To evaluate the safety and effectiveness of bispecific antibodies, a systematic review of existing literature and clinical trials was conducted. Data were collected from databases such as PubMed and ClinicalTrials.gov, as well as from announcements at international conferences. The studies included in this review focus on the application of these antibodies in patients with hematological malignancies. Results: The review identified 31 clinical studies supporting the use of bispecific antibodies in the treatment of hematological malignancies. The findings indicate that these antibodies can provide significant clinical benefits, particularly for patients who have exhausted other therapeutic options. Treatments with bispecific antibodies, such as teclistamab and glofitamab, have shown high response rates and prolonged survival. Specifically, overall survival (OS) of patients increased significantly with the use of these antibodies. Conclusions: Bispecific antibodies represent an innovative approach in the treatment of hematological malignancies, with substantial therapeutic potential. Clinical study results suggest that the use of these antibodies can extend the overall survival of patients and improve their quality of life. However, adverse effects were observed, with the most common including infections, injection site reactions, and cytopenias. Overall, bispecific antibodies appear to be a promising therapeutic option, but further research is needed to fully evaluate their long-term safety and effectiveness. The choice of endpoints plays a decisive role in the scientific validity and in the evaluation of the efficacy and safety of the treatment under study. So to choose the most useful endpoint, we need to take into consideration the design of each study.
Keywords:
Bispecific antibodies, Hematological malignancies, Lymphoma, Multiple myeloma, Systematic review
